- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04902807
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation (ATRACTion)
Study Overview
Status
Conditions
- Autoimmune Diseases
- Systemic Lupus Erythematosus
- Primary Immunodeficiency
- Autoimmune Hepatitis
- Juvenile Idiopathic Arthritis
- IBD
- Autoimmune Rheumatologic Disease
- Autoimmune Diabetes
- APECED
- IPEX
- Hemophagocytic Lymphohistiocytoses
- Autoimmune Lymphoproliferative Syndrome
- Autoimmune Thrombocytopenia
- Autoimmune Cytopenia
- Autoimmune Anemia
- EBV Lymphoproliferation
- RAS-Associated Autoimmune Leucoproliferative Disease
- BENTA
- Enteropathy, Autoimmune
- Combined Immunodeficiency
Intervention / Treatment
Detailed Description
Primary Immune deficiencies (PIDs) are a group of monogenic diseases related to developmental or functional dysfunction of one or several immune cell types. Individually there are rare entities, but collectively they group several thousands of patients.
Approximately 500 000 patients suffer from PIDs worldwide, making their management a true health-care concern. According to European Society for Immunodeficiencies (ESID), the age group in which PIDs is most frequently diagnosed is under 19 years of age (62%)1. PIDs are causing susceptibility to severe and life-threatening infections by common pathogens, but they also predispose to cancer and can initially manifest as autoimmune and inflammatory diseases.
Multiple mechanisms underlie the development of autoimmunity/inflammation in PIDs. Moreover, their development can be influenced by the composition of the microbiota, which shapes host metabolic and immune functions and can be modified by many environmental factors. In the last two decades a particular emphasis was given to the elucidation of the genomic mutations causing PIDs. This led to a burst of genetic diagnosis as the numbers of known monogenic causes of PIDs rose from around 200 in 2010 to more than 310 in 2017. These genomic approaches revealed that: 1) a given monogenic defect can lead to very dissimilar clinical presentations, disproving the initial concept that a monogenic defect is associated with specific clinical manifestations ; and 2) the number of cases of autosomal dominant genetic deficiencies has increased, with sometimes a partial clinical penetrance so that some relatives carrying the causal genetic variant remain asymptomatic. Hence, onset and presentation of autoimmune and inflammatory diseases in PIDs is highly unpredictable.
PIDs with autoimmunity/inflammation usually require life-long symptomatic treatments including broad immunosuppression or immunotherapies. On the long term, such treatments can have important side effects or poor efficacy and they result in high burden cost. It is therefore crucial to diagnose PIDs as early as possible in order to select the most efficient therapy based not only on clinical features as it is nowadays, but to include the underlying molecular cause of immune dysregulation.
The central goal of this project is to explain the very variable outcome of monogenic autoimmune and inflammatory diseases and to define predictive biomarkers in order to stratify patients and to optimize therapeutic choices.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Didier Beudin
- Phone Number: +33 1 42 75 46 42
- Email: didier.beudin@inserm.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients with PIDs and autoimmunity/inflammation related to known and unknown genetic defects (ALPS, Cytopenia, Enteropathy-IBD, pSLE, JIA, FHL, CA-EBV, CID) and their healthy relatives (controls) will be recruited in 2 clinical services of Necker hospital: Paediatric Rhumatology Immuno Hematology department Department, and paediatric Paediatric Gastroenterology department Department.
Unrelated controls will be recruited in the Paediatric Rhumatology Immuno Hematology Department, the Paediatric Gastroenterology Department,also be recruited in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery within patients hospitalised for a surgery and not affected by an immune-related disease or a cancer.
Description
Inclusion Criteria for controls (patients relatives and unrelated subjects):
- Individuals aged<18 y/o.
- Individuals > 6 kg
- Individuals not affected by an immune-related disease or not affected by cancer
- Individuals whose parents have signed an enlightened consent.
Inclusion criteria for patients
- Individuals with health insurance.
- Patients treated at Necker hospital with PIDs and autoimmunity/inflammation related to known genetic defects (cytopenia, Enteropathy Inflammatory bowel disease (IBD), Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic Arthritis (JIA), Familial Hemophagocytic Lymphohistiocytosis (FHL), chronic EBV infection associated (Ca-EBV) with EBV-infected T and/or Natural Killer (NK) cells and with a high risk to develop macrophage activation syndrome similar to FHL. See table below for diagnosis inclusion criteria.
- Individuals aged<18 y/o.
- Individuals > 9 kg
- Patients whose parents have signed an enlightened consent.
Exclusion Criteria:
- Intake of antibiotics within 2 weeks prior inclusion
- Absence of parent's or child consent form
- Cytotoxic cancer treatments
- antiviral treatments (HIV, hepatitis …)
- Short term life-threatening conditions
- Individuals placed under judicial protection
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients
based on the potential for inclusion of patient's cohort followed in Necker hospital with PIDs and poly-autoimmunity related to known genetic defects. Recruitments will be made at Pediatric Rheumatology Immuno Hematology department, and paediatric Gastroenterology department (n=250). Collection of blood, urine and stools at inclusion and blood at 12 months consultation/ follow-up. |
Blood, Urine and Stool samples will be collected from the participants.
|
Patients' relatives (control)
Brothers or sisters of the patients (n=125).
Collection of blood, urine and stools at inclusion.
|
Blood, Urine and Stool samples will be collected from the participants.
|
Patients with unrelated diseases (control)
Recruitments will be made at the Paediatric Gastroenterology Department, in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery at Necker's Hospital. Participants will be included if not diagnosed PIDs and poly-autoimmunity (n=125). Collection of blood, urine and stools. |
Blood, Urine and Stool samples will be collected from the participants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Generate a diagnosis and therapeutic-decision tools
Time Frame: 5 years
|
Identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomic, epigenomics, proteomic, metagenomic, metabolomics and lipidomics).
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1- Development of an atlas of molecular interactions leading to autoimmunity and inflammation
Time Frame: 5 years
|
Research tool integrating transcriptomic, proteomic, epigenetic, metabolomic and lipidomics data of pediatric affected patients as well as healthy pediatric individuals This atlas will be available widely to the public and private research community.
|
5 years
|
2 - To develop an artificial intelligent online application
Time Frame: 5 years
|
The decision support tool will be interoperable with any clinical information system and will be clinically validated.
|
5 years
|
3- Ancillary study (pilot study)
Time Frame: 5 years
|
i. Validation of candidate biomarkers associated to diagnosis and prognosis of Juvenile Idiopathic Arthritis patients ; ii.
Definition of a specific clinical outcome and early quantification of the performance of a diagnostic decision tool based on omics signatures (proof of concept)
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Frédéric Rieux-Laucat, Institut Imagine
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Endocrine System Diseases
- Hematologic Diseases
- Diabetes Mellitus
- Hemorrhage
- Liver Diseases
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Joint Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Arthritis
- Hepatitis, Chronic
- Blood Coagulation Disorders
- Skin Manifestations
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Hepatitis
- Histiocytosis, Non-Langerhans-Cell
- Histiocytosis
- Purpura, Thrombocytopenic
- Purpura
- Diabetes Mellitus, Type 1
- Lupus Erythematosus, Systemic
- Inflammation
- Immunologic Deficiency Syndromes
- Primary Immunodeficiency Diseases
- Rheumatic Diseases
- Collagen Diseases
- Purpura, Thrombocytopenic, Idiopathic
- Thrombocytopenia
- Autoimmune Diseases
- Hepatitis, Autoimmune
- Arthritis, Juvenile
- Lymphohistiocytosis, Hemophagocytic
- Autoimmune Lymphoproliferative Syndrome
Other Study ID Numbers
- C20-59
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiRecruitingHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on Collection of samples
-
Centre Hospitalier Universitaire de NiceCompletedUrinary Tract InfectionsFrance
-
Innovaderm Research Inc.RecruitingPlaque Psoriasis | Atopic Dermatitis | Hidradenitis Suppurativa | Palmoplantar Pustulosis | Acne | Chronic Hand EczemaCanada
-
Centre Hospitalier René DubosCompletedCoronavirus InfectionFrance
-
Centre Francois BaclesseLigue contre le cancer, France; Fondation de France; Centre National de la Recherche...Recruiting
-
ARCTECCardiff University; Durham University; Medical Detection DogsUnknown
-
University Hospital, Strasbourg, FranceCompletedRheumatoid Arthritis | Systemic Lupus ErythematosusFrance
-
Yakult Honsha European Research Center, ESVHarmony Clinical Research BVBACompleted
-
University of ZurichUnknownPustular Psoriasis | Erosive Pustular Dermatosis of the Scalp | Behcet's Disease | Dermatitis Herpetiformis | Pyoderma Gangrenosum | Linear IgA Bullous Dermatosis | Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue | Sweet's Syndrome | Bowel-associated Dermatosis-arthritis Syndrome | Acute Generalized Exanthematous Pustulosis and other conditionsSwitzerland
-
Nantes University HospitalNot yet recruiting
-
Hopital FochRecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant Failure and RejectionFrance